Contineum Therapeutics narrows loss as R&D costs decline
The biotechnology company reported a net loss of $15.2 million for the second quarter of 2026.
Contineum Therapeutics (CTNM) reported a net loss of $15.2 million for the second quarter of 2026. The biotechnology company narrowed its quarterly loss from the $16.0 million reported in the same period last year.
The result followed a strategic pivot to streamline discovery programs. The company shifted its focus exclusively toward inflammatory and fibrotic diseases, a move that included a workforce reduction and the departure of Chief Scientific Officer Daniel Lorrain, Ph.D..
Research and development expenses fell 10% year-over-year to $12.7 million. The decline was due to the completion of the PIPE-307 VISTA trial and lower costs associated with the PIPE-791 chronic pain trial, though these savings were partially offset by expenses for the PIPE-791 IPF program.
General and administrative expenses rose 23% year-over-year to $4.7 million. The increase was primarily due to higher employee-related costs and stock-based compensation.
Clinical activity continued across several programs. Johnson & Johnson completed enrollment for the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in June 2026 with 107 adult participants, fewer than the 124 participants the company had previously estimated. Additionally, the PROPEL-IPF Phase 2 trial expanded to more than 55 sites across eight countries to facilitate enrollment.
On April 30, 2026, the company reported positive topline data from an exploratory Phase 1b trial of PIPE-791 for chronic pain, which met its primary objective of safety and tolerability.
Cash, cash equivalents, and marketable securities totaled $236.6 million as of June 30, 2026. This represented a decrease from the $246.3 million the company held as of March 31, 2026.